New cholesterol-lowering ingredient
This article was originally published in The Tan Sheet
Next Pharmaceuticals announces Dec. 5 its patented heart-health ingredient Flavoxine is clinically shown to increase HDL-cholesterol while "significantly reducing" LDL-cholesterol and triglycerides. The double-blind, placebo-controlled clinical trial included 80 subjects. "The active compounds from the plants used have been studied extensively and therefore Flavoxine does not have the risks frequently associated with new synthetic compounds," says Next Pharmaceuticals President and CEO Bob Garrison. The Carlsbad, Calif.-based company says Flavoxine is a blend of a proprietary extract of Phellodendron amurense and a patented extract of orange peel containing polymethoxylated flavones. The firm says the ingredient will be available to consumer product manufacturers in January...
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.